WCN26-3268 PLASMA GALECTIN-9 AS A BIOMARKER OF MESANGIAL EXPANSION AND OUTCOMES IN BIOPSY-PROVEN KIDNEY DISEASE

Read full text Summarise with VIRAT
Authors: Ming‐Tsun Tsai, Szu‐Yuan Li, T S Chen, Shuo‐Ming Ou
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Galectin-9 (Gal-9) is a potential biomarker for renal disease; however, its role in chronic kidney disease (CKD) progression remains underexplored. In this study, we investigated the association between plasma Gal-9 levels and kidney histopathology, as well as its prognostic value for major adverse renal events (MARE) in patients with biopsy-proven kidney disease.

Fields of Study & Subjects

Chronic Kidney Disease and Diabetes Galectins and Cancer Biology Renal Diseases and Glomerulopathies

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104315–104315
Publication date
25 March 2026
Language
EN